Johannes Holtschmidt

Neu Isenburg, HE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.

Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 18, 2026

Surgical axillary intervention after neoadjuvant systemic therapy (NST) for early-stage breast cancer - Clinical significance of micrometastases: Data from five neoadjuvant studies.

Surgical axillary intervention after neoadjuvant systemic therapy (NST) for early-stage breast cancer - Clinical significance of micrometastases: Data from five neoadjuvant studies.

Journal: Breast (Edinburgh, Scotland)

Published: January 05, 2026

First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study.

First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study.

Journal: ESMO open

Published: December 10, 2025

Axillary surgery in patients with sentinel node macrometastases: secondary results of the randomized INSEMA trial.

Axillary surgery in patients with sentinel node macrometastases: secondary results of the randomized INSEMA trial.

Journal: NPJ breast cancer

Published: December 04, 2025

Challenges and strategies for delivering effective breast cancer care in conflict zones.

Challenges and strategies for delivering effective breast cancer care in conflict zones.

Journal: Communications medicine

Published: October 07, 2025

Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX).

Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX).

Journal: ESMO open

Published: June 18, 2025

Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials.

Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials.

Journal: The Lancet. Oncology

Published: March 13, 2025

Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy.

Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 03, 2025

Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer.

Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 30, 2025

Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial.

Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial.

Journal: The New England journal of medicine

Published: December 12, 2024

Shifting the Paradigm: The Transformative Role of Neoadjuvant Therapy in Early Breast Cancer.

Shifting the Paradigm: The Transformative Role of Neoadjuvant Therapy in Early Breast Cancer.

Journal: Cancers

Published: September 05, 2024

Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD-Long-term Survival of the GeparOLA Study.

Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD-Long-term Survival of the GeparOLA Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 27, 2024

Showing 1-12 of 33

Last Updated: 09/26/2026